Tag: kinase inhibitors market scope

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Kinase Inhibitors Market from 2024 to 2033?
The kinase inhibitors market has shown robust growth, projected to grow from $58.49 billion in 2023 to $62.75 billion in 2024, with a CAGR of 7.3%. This growth is driven by the increasing prevalence of cancer, advancements in targeted therapies, rising healthcare spending, and new approvals of kinase inhibitors.

The kinase inhibitors market is projected to grow steadily, reaching $83.56 billion by 2028 at a CAGR of 7.4%. This growth is fueled by ongoing R&D, novel inhibitor introductions, and increased precision medicine awareness. Trends include precision oncology treatments and advancements in biomarker-driven drug development.

Claim Your Free Sample of the Global Kinase Inhibitors Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15841&type=smp

What Key Factors Are Fueling the Growth of the Kinase Inhibitors Market?
The rising incidence of autoimmune diseases is projected to drive the growth of the kinase inhibitors market. Autoimmune diseases involve abnormal immune responses where the body attacks its healthy cells, influenced by lifestyle changes, environmental factors, genetic predispositions, and chronic diseases like obesity and diabetes. Kinase inhibitors provide therapeutic benefits by modulating the immune system and alleviating symptoms of conditions like psoriatic and rheumatoid arthritis. For instance, in December 2022, the National Psoriasis Foundation reported that over 8 million people in the U.S. were affected by psoriasis. Additionally, the CDC indicated that 28.7 million Americans had diabetes. Therefore, the increase in autoimmune diseases is propelling the kinase inhibitors market.

What Are the Major Segments of the Kinase Inhibitors Market?
1) By Type: Tyrosine Kinase Inhibitors, Multikinase Inhibitors, mTOR Kinase Inhibitors, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Application: Oncology, Inflammatory Diseases
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

What New Trends Are Transforming the Kinase Inhibitors Market?
Companies in the kinase inhibitors market are developing selective tyrosine kinase 2 (TYK2) inhibitors to meet treatment needs for autoimmune diseases. For example, in September 2022, Bristol-Myers Squibb Company, a US pharmaceutical firm, received FDA approval for Sotyktu (deucravacitinib), an oral TYK2 inhibitor for treating moderate-to-severe plaque psoriasis in adults.

Order Now for Fast Delivery of Your Kinase Inhibitors Market Report!
https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Which Regions Are Driving Growth in the Kinase Inhibitors Market?
Asia-Pacific was the largest region in the kinase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Kinase Inhibitors Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the kinase inhibitors market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Kinase Inhibitors Market Include

1. Kinase Inhibitors Market Executive Summary
2. Kinase Inhibitors Market Segments
3. Kinase Inhibitors Market Size And Template Market Growth Rate
4.  Key Kinase Inhibitors Market Trends
5. Major Kinase Inhibitors Market Drivers
……
25. Key Mergers And Acquisitions In The Kinase Inhibitors Market
26. Top Kinase Inhibitors Companies
27. Kinase Inhibitors Market Opportunities And Strategies
28. Kinase Inhibitors Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:
Global Tyrosine Kinase Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report

Janus Kinase (JAK) Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

CDK 4/6 Inhibitor Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cyclin-dependent-kinase-cdk-4-or-6-inhibitor-drugs-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

The kinase inhibitors market has been experiencing robust growth and is poised for further expansion in the coming years. Here’s a closer look at the factors driving this market, key trends, and recent developments shaping its future.

Market Overview and Growth Drivers

• Strong Market Growth: The kinase inhibitors market grew from $58.49 billion in 2023 to $62.75 billion in 2024, with a compound annual growth rate (CAGR) of 7.3%.
• Historical Growth Factors: This growth can be attributed to several factors:
  • Increasing prevalence of cancer.
  • Advancements in targeted therapy.
  • Rising healthcare expenditure.
  • Approval of new kinase inhibitors.
  • Growing adoption of personalized medicine.

Future Market Projections

• Continued Market Expansion: The kinase inhibitors market is expected to grow to $83.56 billion by 2028 at a CAGR of 7.4%.
• Key Growth Drivers: Several factors are expected to propel market growth in the forecast period:
  • Ongoing research and development activities.
  • Introduction of novel kinase inhibitors.
  • Expanding applications beyond oncology.
  • Increasing investment in biotechnology.
  • Growing awareness about precision medicine.

Read More On The Kinase Inhibitors Market Report 2024 – https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Trends Shaping the Future of Kinase Inhibitors

• Expansion of Precision Oncology Treatments: Increasing focus on developing therapies tailored to individual genetic profiles.
• Development of Combination Therapies: Combining different kinase inhibitors to enhance treatment efficacy and overcome resistance.
• Focus on Rare and Hard-to-Treat Cancers: Addressing unmet needs in treating challenging cancer types.
• Advancements in Biomarker-Driven Drug Development: Utilizing biomarkers to identify patients who are most likely to benefit from specific kinase inhibitors.
• Adoption of Next-Generation Sequencing Technologies: Leveraging advanced sequencing technologies for better understanding of cancer genetics and more precise treatment strategies.

Rising Autoimmune Diseases Drive Market Growth

• Increasing Cases of Autoimmune Diseases: Autoimmune diseases are a significant driver of growth in the kinase inhibitors market.
  • These diseases involve abnormal immune responses, where the immune system attacks healthy cells.
  • The prevalence of autoimmune diseases is increasing due to various factors, including lifestyle changes, genetic predisposition, and the rise in chronic diseases like obesity and diabetes.
• Role of Kinase Inhibitors: Kinase inhibitors help manage autoimmune diseases by modulating the immune system and reducing inflammation.
  • For example, they are used to treat conditions like psoriatic and rheumatoid arthritis.

Advances in TYK2 Inhibitors for Autoimmune Diseases and Cancer

• Development of Selective TYK2 Inhibitors: Major companies are developing selective tyrosine kinase 2 (TYK2) inhibitors to address unmet needs in autoimmune and inflammatory diseases.
  • These inhibitors modulate immune responses and reduce inflammation, which can enhance the body’s ability to target and destroy cancer cells.
• Notable Example: In September 2022, Bristol-Myers Squibb received approval for Sotyktu (deucravacitinib) from the U.S. FDA.
  • Sotyktu is an oral selective TYK2 inhibitor for treating moderate-to-severe plaque psoriasis in adults.

Strategic Moves in the Kinase Inhibitors Market

• Bristol Myers Squibb’s Acquisition of Turning Point Therapeutics: In August 2022, Bristol Myers Squibb acquired Turning Point Therapeutics Inc. for $4.1 billion.
  • This acquisition expanded Bristol Myers Squibb’s oncology portfolio, adding a late-stage kinase inhibitor candidate in repotrectinib.
  • The deal strengthens Bristol Myers Squibb’s position in treating ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors.

Market Segmentation

• By Type: Tyrosine Kinase Inhibitors, Multikinase Inhibitors, mTOR Kinase Inhibitors, Other Types.
• By Route of Administration: Oral, Parenteral, Other Routes.
• By Application: Oncology, Inflammatory Diseases.
• By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
• By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users.

Regional Insights

• Largest Market: Asia-Pacific was the largest region in the kinase inhibitors market in 2023.
• Fastest-Growing Region: Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by rising healthcare investments, increasing prevalence of chronic diseases, and expanding access to advanced therapies.

The kinase inhibitors market is on a strong growth trajectory, driven by advancements in targeted therapies and increasing demand for precision medicine. With ongoing innovations and strategic acquisitions, the market is set to expand further, offering new opportunities for stakeholders in the healthcare sector.

Request for A Sample Of The Global Kinase Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=15841&type=smp